Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- FY2016 Reimbursement Policy Reform “Tough” on Industry: JPMA
February 19, 2016
- Top MHLW Bureaucrat Says 80% Generic Share “Achievable”
February 16, 2016
- Former JMA Pres. Eitaka Tsuboi Dies at 86
February 15, 2016
- EFPIA Japan Lays Out Basic Principles on MSL Activities
February 4, 2016
- Japanese Pharma Market to Shrink 30% over 10 Years with Annual Revisions: New PhRMA Japan Chief
January 22, 2016
- JPMA Expels Kaketsuken over GMP Violations, Cover-Up
January 22, 2016
- PhRMA Japan Representative Ira Wolf Dies at 70
January 19, 2016
- JPMA Head Hints “Free Pricing” Could Be an Option in System Overhaul
January 18, 2016
- JPMA Unveils Pharma Industry Vision 2025
January 18, 2016
- PhRMA Picks Amy Jackson as New Japan Representative
January 15, 2016
- Mandatory Cancer Registration Gets Underway in Japan
January 14, 2016
- JGA Takes Sincerely 50% Pricing Rule for First Generics, There’s Limitation to Data Collection: Chief
January 13, 2016
- EFPIA Japan Chief Raps Huge Seller Re-Pricing, Says April Reform Will Chill the Market
January 8, 2016
- April Drug Price Revision “Will Be a Hard One” for the Industry: Pharma Leader Nakayama
January 7, 2016
- JPWA President Expresses Opposition to Market Price Survey in Conjunction with Sales Tax Hike, Calls for “Simplified Survey” If Necessary
January 6, 2016
- JGA Deeply Sorry for Making Baseless Demand on FY2016 Drug Pricing Reform
January 5, 2016
- Re-Pricing of Huge Seller Drugs “Extremely Unreasonable”: FPMAJ
January 5, 2016
- FPMAJ Chief Says It’s Time for Social Security Overhaul, Sub-Optimization Has Reached Limit
January 5, 2016
- Special Re-Pricing of Huge-Seller Drugs “Unacceptable,” JPMA Says on FY2016 Reform
December 25, 2015
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…